ViiV lealthcare

Efficacy and Safety of Switching to DTG/3TC in Virologically Suppressed PLWH by Age, Including Those Aged ≥65 Years: Pooled Results From the TANGO and SALSA Studies

Manyu Prakash,¹ Richard Grove,² Brian Wynne,³ Choy Man,³ Jean van Wyk,¹ Bryn Jones,¹ Chinyere Okoli,¹ Emilio Letang,⁴ Mounir Ait-Khaled,¹ Andrew Clark¹ ¹ViiV Healthcare, Brentford, UK; ²GSK, Brentford, UK; ³ViiV Healthcare, Durham, NC, USA; ⁴ViiV Healthcare, Madrid, Spain

Key Takeaways

This pooled analysis of the TANGO and SALSA studies shows that virologically suppressed participants aged <50, ≥50 to <65, and ≥65 years switching to DTG/3TC maintained high levels of suppression with comparable safety outcomes and no resistance development across age groups at Week 48 despite increasing concomitant non-ART medication use and comorbidities with age

There was a low and comparable risk of ≥10% weight gain with DTG/3TC vs continuing current antiretroviral regimen (CAR) across all age groups

These data support DTG/3TC as a suppressed switch option in older adults living with HIV, including both those aged ≥50 and ≥65 years

Introduction


- Predictive modeling using cohorts from the United States and Netherlands has estimated that by 2030, ≥70% of people living with HIV (PLWH) will be aged \geq 50 years,^{1,2} yet this demographic is underrepresented in HIV clinical trials^{3,4}
- As populations of PLWH age, treatment requirements to support healthy living with HIV extend beyond achieving and maintaining virologic suppression to also managing agerelated comorbidities, polypharmacy, and other healthcare priorities^{5,6}
- DTG/3TC is an international guidelines—recommended 2-drug regimen demonstrating durable efficacy, high barrier to resistance, and good safety and tolerability⁷ as a suppressed switch option in the phase 3 TANGO and SALSA studies^{8,9}
- Here, we present pooled TANGO and SALSA efficacy and safety results analyzed by age (<50, \geq 50 to <65, and \geq 65 years)

Methods

Study Design

• This analysis included pooled Week 48 data from the open-label phase 3 TANGO and SALSA trials evaluating switch to once-daily DTG/3TC fixed-dose combination or continuing CAR (Figure 1)^{8,9}

Figure 1. Study Design



1) in both studies was stratified by baseline third agent class (PI, INSTI, or NNRTI). ^aParticipants with initial TDF treatment who switched to TAF \geq 3 months before screening, with no changes to other drugs in their regimen, were also eligible. ^bParticipants were on uninterrupted ART regimen for \geq 3 months.

- Proportions of participants with HIV-1 RNA ≥50 c/mL and <50 c/mL (Snapshot, ITT-E) and safety parameters were analyzed by age categories (<50 and \geq 50 years or <50, \geq 50 to <65, and \geq 65 years)
- Mixed-models repeated-measures analyses were used for adjusted mean change from baseline in CD4+ cell count, CD4+/CD8+ ratio, and renal biomarkers in the <50- vs ≥50-year age groups
- Adjustment terms were treatment, visit, sex, age, race, baseline third agent class, baseline CD4+ cell count, baseline BMI, treatment-by-visit interaction, baseline value-by-visit interaction, visit-by-age interaction, treatment-by-age interaction, treatment-by-visit-by-age interaction, and study, with visit as the repeated factor
- For CD4+/CD8+ ratio, baseline CD4+/CD8+ ratio was an additional adjustment term
- For renal biomarkers, diabetes and hypertension were additional adjustment terms

IDWeek 2022; October 19-23, 2022; Virtual and Washington, DC

- Logistic Firth regression model analysis was used to determine treatment regimen adjusted likelihood of ≥10% weight gain at Week 48
- Adjustment terms were treatment, sex, age, race, baseline third agent class, baseline CD4+ cell count, baseline weight, and study

Results

Participants

- Of 1234 participants in the pooled TANGO and SALSA ITT-E population (DTG/3TC, n=615; CAR, n=619), 71% (n=870) were aged <50 years, 26% (n=321) were aged \geq 50 to <65 years, and 3% (n=43) were aged \geq 65 years (Table 1)
- Overall demographics and baseline characteristics were balanced among age groups and between treatment groups except for longer duration of ART before baseline with increasing age


Table 1. Demographics and Baseline Characteristics Overall and by Age: Pooled **TANGO and SALSA ITT-E Population**

	Overall		<50 y		≥50 to <65 y		≥65 y		
Parameter	DTG/3TC	CAR	DTG/3TC	CAR	DTG/3TC	CAR	DTG/3TC	CAR	
	(N=615) ^a	(N=619) ^b	(N=438) ^c	(N=432) ^d	(N=163) ^e	(N=158)	(N=14)	(N=29)	
Sex at birth, n (%) Male Female	482 (78) 133 (22)	502 (81) 117 (19)	370 (84) 68 (16)	361 (84) 71 (16)	104 (64) 59 (36)	120 (76) 38 (24)	8 (57) 6 (43)	21 (72) 8 (28)	
Age, median	42	42	37	36	56	55	67	69	
(range), y	(20-74)	(18-83)	(20-49)	(18-49)	(50-64)	(50-64)	(65-74)	(65-83)	
Weight, median	77	78	78	77	75	80	72	75	
(range), kg	(43-154)	(36-160)	(43-154)	(48-160)	(44-128)	(36-127)	(59-106)	(49-116)	
BMI, median	25	26	25	25	25	27	26	27	
(range), kg/m²	(17-51)	(14-69)	(17-51)	(17-69)	(18-43)	(14-45)	(18-32)	(19-44)	
Baseline CD4+ cell	680	684	685	686	653	677	638	657	
count, median	(133-	(94-	(154-	(94-	(133-	(119-	(228-	(122-	
(range), cells/mm ³	2089)	1954)	1904)	1954)	2089)	1530)	1199)	1133)	
Baseline CD4+/CD8+ ratio, mean (SD)	1.1 (0.54)	1.1 (0.50)	1.0 (0.51)	1.0 (0.44)	1.1 (0.61)	1.1 (0.65)	1.2 (0.58)	1.0 (0.46)	
Duration of ART before Day 1, median (range), mo	41 (4-240)	45 (7-253)	37 (4-188)	41 (7-206)	61 (7-240)	57 (9-253)	58 (8-201)	74 (20-214)	

^aN=614 for CD4+ cell count; N=611 for CD4+/CD8+ ratio. ^bN=618 for weight, BMI, and CD4+/CD8+ ratio. ^cN=436 for CD4+/CD8+ ratio. ^dN=431 for weight, BMI, and CD4+/CD8+ ratio. ^eN=162 for CD4+ cell count; N=161 for CD4+/CD8+ ratio.


• Proportions of participants with baseline non-ART medication use (Figure 2) and comorbidities (Figure 3) increased with age in both treatment groups






Acknowledgments: These studies were funded by ViiV Healthcare. The authors thank the study participated in the TANGO and SALSA studies; and the ViiV Healthcare and GSK study team members. Editorial assistance and graphic design support for this poster were provided under the direction of the authors by MedThink SciCom and funded by ViiV Healthcare.

Virologic and Immunologic Outcomes • Proportions of participants with HIV-1 RNA <50 c/mL were high across all age and treatment groups at Week 48 (Figure 4)



• Proportions with HIV-1 RNA ≥50 c/mL were low across all age and treatment groups • No participants aged ≥65 years had HIV-1 RNA≥50 c/mL





 No participants in the DTG/3TC group had confirmed virologic withdrawal (CVW); 1 participant in the CAR group had CVW (aged <50 years; no resistance detected) • Change from baseline in CD4+ cell count and CD4+/CD8+ ratio was consistent with overall results and across age groups (<50 vs \geq 50 years)

- Adjusted mean change (SE) from baseline in CD4+ cell count, DTG/3TC vs CAR, respectively: <50 years, 29.0 (8.5) vs 7.6 (8.2) cells/mm³; ≥50 years, 6.3 (13.6) vs −24.7
- (12.5) cells/mm³; overall, 22.4 (7.2) vs -2.0 (6.9) cells/mm³
- Adjusted mean change (SE) from baseline in CD4+/CD8+ ratio, DTG/3TC vs CAR, respectively: <50 years, 0.039 (0.010) vs 0.048 (0.010); ≥50 years, 0.032 (0.016) vs 0.062 (0.016); overall, 0.037 (0.008) vs 0.052 (0.009)

• Across all age groups, proportions of any AEs were similar between the DTG/3TC and CAR groups, with few AEs leading to withdrawal and higher proportions of drugrelated AEs with DTG/3TC vs CAR; similar results were observed in the overall population (Table 2)

Table 2. Summary of AEs Through Week 48 Overall and by Age: TANGO and SALSA Pooled Safety Population^a



AEs leading withdrawal

Grade 2-5

Drug-relate

Serious AE

- 22/567 [4%])

Conclusions

References: 1. Wing. Trans Am Clin Climatol Assoc. 2017;128:131-144. 2. Smit et al. Lancet Infect Dis. 2015;15:810-818. 3. Johnston and Heitzeg. AIDS Res Hum Retroviruses. 2015;31:85-97. 4. Spinelli et al. HIV Res Clin Pract. 2021;22:46-54. 5. Lazarus et al. Nat Commun. 2021;12:4450. 6. The Antiretroviral Therapy Cohort Collaboration. Lancet HIV. 2017;4:e349-e356. 7. Saag et al. JAMA. 2020;324:1651-1669. 8. Osiyemi et al. Clin Infect Dis. 2022 [Epub ahead of print]. 9. Llibre et al. Clin Infect Dis. 2022 [Epub ahead of print]. 10. Hagins et al. CROI 2022; Virtual. Poster 603.



Presenting author: **Emilio Letang** P.T.M., Severo Ochoa 2 28760 Tres Cantos, Madrid, Spain emilio.x.letang@viivhealthcare.com Phone: +34 677571603



	Overall		<5(0 y	≥50 to	<65 y	≥65 y	
	DTG/3TC (N=615)	CAR (N=618)	DTG/3TC (N=438)	CAR (N=432)	DTG/3TC (N=163)	CAR (N=157)	DTG/3TC (N=14)	CAR (N=29)
	475 (77)	464 (75)	333 (76)	330 (76)	133 (82)	113 (72)	9 (64)	21 (72)
ng to I	18 (3)	5 (<1)	11 (3)	2 (<1)	7 (4)	2 (1)	0	1 (3)
	281 (46)	303 (49)	189 (43)	206 (48)	85 (52)	82 (52)	7 (50)	15 (52)
ed	93 (15) ^ь	21 (3) ^c	65 (15)	18 (4)	25 (15)	3 (2)	3 (21)	0
∃s ^d	28 (5)	32 (5)	18 (4)	16 (4)	8 (5)	12 (8)	2 (14)	4 (14)

^aIn TANGO, 1 participant was found to be taking a TDF-based regimen and was excluded from the safety population. ^bThe most common (≥0.5%) grade 2-5 drug-related AEs reported were grade 2 insomnia (7/615 [1.1%]) and weight increase (4/615 [0.7%]); there were no grade \geq 3 drug-related AEs. ^cThe most common grade 2-5 drug-related AE was grade 2 gastroesophageal reflux disease (2/618 [0.3%]); 2 grade 3 drug-related AEs were reported (hypertriglyceridemia (1/618 [0.2%]) and hypercholesterolemia (1/618 [0.2%]). ^dThere were no drug-related serious AEs.

• Proportions of participants who experienced $\geq 10\%$ weight gain at Week 48 were low across age and treatment groups (DTG/3TC vs CAR: <50 years, 27/411 [7%] vs 17/396 [4%]; ≥50 years, 11/161 [7%] vs 5/171 [3%]; overall, 38/573 [7%] vs

• Proportions with $\geq 10\%$ weight gain were slightly higher in the DTG/3TC vs CAR group across age groups (<50 years: OR, 1.63; 95% CI, 0.88-3.11; ≥50 years: OR, 1.63; 95% CI, 0.57-5.12) and overall (OR, 1.71; 95% CI, 0.996-2.99)

• Weight differences were primarily driven by SALSA outcomes, where CAR included weight-suppressive antiretroviral agents (TDF and EFV)¹⁰

• Odds of $\geq 10\%$ weight gain were higher in the DTG/3TC vs CAR group across age groups in SALSA (<50 years: OR, 2.97; 95% CI, 1.21-8.22; ≥50 years: OR, 2.23; 95% CI 0.57-11.22) vs TANGO (<50 years: OR, 0.88; 95% CI, 0.36-2.13; ≥50 years: OR, 1.30; 95% CI not evaluable)

• Change from baseline in estimated glomerular filtration rate (eGFR) based on serum cystatin C was consistent within age groups (<50 vs ≥50 years) between groups • Adjusted mean (SE) change from baseline in eGFR based on serum cystatin C for DTG/3TC vs CAR, respectively: <50 years, 0.812 (0.56) vs 0.003 (0.56) mL/min/1.73 m²; \geq 50 years, -3.79 (0.93) vs -4.55 (0.89) mL/min/1.73 m²; overall, -0.53 (0.46) vs -1.34 (0.45) mL/min/1.73 m²

• Among PLWH, switching to DTG/3TC maintained high rates of virologic suppression, maintained baseline immunologic status with further CD4+ recovery, had a high barrier to resistance, and was well tolerated across all age groups, including among those aged ≥65 years

• As non-ART medication use and comorbidities increase with age, a well-tolerated 2-drug regimen with robust efficacy may help with the clinical management of older PLWH at risk of polypharmacy-driven drug-drug interactions

• DTG/3TC is a durable and robust HIV therapeutic option among older people with evolving health needs and comorbidities



This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their licence. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.